Erector Spinae Plane Blocks for Pain Control After Total Laparoscopic Hysterectomy
Effects of Erector Spinae Plane Block and Deep Erector Spinae Plane Block on Postoperative Pain Management in Total Laparoscopic Hysterectomy
This study will compare two nerve block techniques for pain relief after total laparoscopic hysterectomy, a minimally invasive operation to remove the uterus. Both techniques involve injecting a local anesthetic near muscles of the lower back, but the injections are given at different depths.
Women aged 18 to 65 years who are scheduled for this surgery will be randomly assigned to one of three groups: erector spinae plane block, deep erector spinae plane block, or no nerve block. The nerve blocks will be performed on both sides of the lower back after surgery. All participants will receive standard pain medication.
The main aim is to compare pain scores one hour after surgery. The study will also assess pain during the first 24 hours, opioid pain medication use, the time until additional pain relief is needed, nausea and vomiting, time to hospital discharge, patient satisfaction, and quality of recovery.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This single-center, prospective, randomized controlled study will compare ultrasound-guided bilateral erector spinae plane block and deep erector spinae plane block with a control group receiving no block in women undergoing total laparoscopic hysterectomy under general anesthesia.
Participants will be allocated to three groups using computer-generated randomization. Blocks will be performed postoperatively in the recovery unit at the L1 vertebral level. In the erector spinae plane block group, the injection will be administered between the erector spinae muscle and the transverse process. In the deep erector spinae plane block group, the injection will be administered deep to the transverse process, in the plane between the erector spinae and psoas muscles. Both block groups will receive 20 mL of 0.25% bupivacaine on each side. The control group will receive no block.
All groups will receive standardized general anesthesia and perioperative multimodal analgesia. Intravenous meperidine at 0.25 mg/kg will be administered as rescue analgesia when the numerical rating scale pain score exceeds 3.
An anesthesiologist blinded to group allocation will assess pain at rest and during movement. Baseline pain scores (0 minutes) will be recorded before block administration. Subsequent pain assessments in the block groups will be timed from completion of bilateral block administration. In the control group, an equivalent reference time will be established in the postoperative recovery unit, and the same assessment schedule will be followed. Postoperative assessments will include pain scores, opioid consumption, rescue analgesic requirements, nausea and vomiting, discharge time, patient satisfaction, and quality of recovery using the Quality of Recovery-15 questionnaire.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Hande Gurbuz, Prof, MD, PhD
- Número de telefone: +90 533 651 56 50
- E-mail: handegrbz@gmail.com
Locais de estudo
-
-
Bursa
-
Bursa, Bursa, Turquia (Türkiye), 16110
- University of Health Sciences, Bursa City Hospital
-
Contato:
- Hande Gurbuz, Prof, MD, PhD
- Número de telefone: +90 533 651 56 50
- E-mail: handegrbz@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female patients aged 18 to 65 years.
- Scheduled for elective total laparoscopic hysterectomy.
- American Society of Anesthesiologists (ASA) physical status I, II, or III.
- Provision of written informed consent.
Exclusion Criteria:
- ASA physical status IV or higher.
- Inability to cooperate with pain assessment because of cognitive impairment, a psychiatric condition, or inability to understand Turkish.
- Known allergy to local anesthetics or opioids.
- Body mass index greater than 35 kg/m².
- Infection at the planned injection site.
- Neurological deficits.
- Alcohol or drug dependence.
- Known or suspected coagulopathy.
- Severe hepatic, cardiac, or renal disease.
- Emergency surgery or repeat surgery.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Erector Spinae Plane Block
Participants will receive an ultrasound-guided bilateral erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae muscle and the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed. |
Ultrasound-guided bilateral erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected between the erector spinae muscle and the transverse process on each side. |
|
Experimental: Deep Erector Spinae Plane Block
Participants will receive an ultrasound-guided bilateral deep erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed. |
Ultrasound-guided bilateral deep erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process, on each side. |
|
Sem intervenção: Control Group
Participants will receive no nerve block. They will receive the same standardized perioperative multimodal analgesia as the two block groups, with rescue analgesia administered as needed. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain Intensity at Rest at 1 Hour After Block Administration
Prazo: At 1 hour after block administration or the equivalent reference time in the control group
|
Pain intensity at rest will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. Assessment will occur 1 hour after completion of bilateral block administration or the equivalent reference time in the control group. |
At 1 hour after block administration or the equivalent reference time in the control group
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain Intensity During Movement at 1 Hour After Block Administration
Prazo: At 1 hour after Block Administration
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. At 1 hour after block administration or the equivalent reference time in the control group |
At 1 hour after Block Administration
|
|
Pain Intensity at Rest Before and After Block Administration
Prazo: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point. |
At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
|
Pain Intensity During Movement Before and After Block Administration
Prazo: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point. |
At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
|
Cumulative Rescue Opioid Consumption During the First 24 Hours After Surgery
Prazo: During the first 24 hours after surgery
|
The total dose of intravenous meperidine administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Rescue analgesia will be administered at a dose of 0.25 mg/kg when the numerical rating scale (NRS) pain score exceeds 3. Higher consumption indicates a greater requirement for rescue opioid analgesia. |
During the first 24 hours after surgery
|
|
Time to First Rescue Analgesia
Prazo: From the end of surgery to the first administration of rescue analgesia, up to 24 hours
|
The time from the end of surgery to the first administration of rescue analgesia will be recorded in minutes. Intravenous meperidine at 0.25 mg/kg will be administered when the numerical rating scale (NRS) pain score exceeds 3. Participants who do not receive rescue analgesia during the first 24 hours will be censored at 24 hours. |
From the end of surgery to the first administration of rescue analgesia, up to 24 hours
|
|
Postoperative Nausea and Vomiting Severity
Prazo: During the first 24 hours after surgery
|
Postoperative nausea and vomiting will be assessed using a five-point scale: 0 = none, 1 = mild nausea, 2 = moderate nausea, 3 = one episode of vomiting, and 4 = more than one episode of vomiting. Higher scores indicate greater severity. |
During the first 24 hours after surgery
|
|
Quality of Recovery at 24 Hours After Surgery
Prazo: Preoperatively and at 24 hours after surgery
|
Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The questionnaire will be administered preoperatively and at 24 hours after surgery. |
Preoperatively and at 24 hours after surgery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Hande Gurbuz, Prof, MD, PhD, University of Health Sciences, Bursa School of Medicine, Bursa City Hospital
Publicações e links úteis
Publicações Gerais
- Baran O. Quadratus lumborum and erector spinae plane blocks are effective for analgesia in laparoscopic hysterectomy: a randomized controlled trial. Eur Rev Med Pharmacol Sci. 2023 Dec;27(23):11323-11333. doi: 10.26355/eurrev_202312_34571.
- Kilicaslan A, Ciftci B, Aycan IO, Arici AG, Kilic G, Cakin H, Yilmaz R, Alver S, Temel H, Sindel M. Lumbar erector spinae plane block: which side of the fascia? The role of injection depth and volume in a cadaveric model. Pain Med. 2026 May 1;27(5):610-612. doi: 10.1093/pm/pnaf171. No abstract available.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 26-AKD-261
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
There is currently no plan to share individual participant data with other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .